NKA Bio

Executive Summary

NKA Bio is a private biotechnology company based in San Diego, founded in 2019 with a mission to improve trauma care by addressing shock. The company's lead product, NKA01, is focused on trauma resuscitation, a critical unmet need in emergency medicine. Additionally, NKA Bio has an early-stage pipeline targeting septic shock, acute lung injury, and heart attack resuscitation. The company aims to develop novel biologics and antibody-based therapies that could significantly improve survival and outcomes in acute care settings. As a preclinical-stage company, NKA Bio has not yet disclosed funding amounts or valuation. Its progress hinges on advancing NKA01 and other programs through development milestones. The company operates in a competitive space but addresses high-mortality conditions with significant clinical need. Near-term catalysts include potential IND filings or preclinical data readouts that could validate its platform and attract partnerships or funding. However, given the early stage, a high degree of risk is associated with regulatory and clinical success.

Upcoming Catalysts (preview)

• Q1 2027IND filing for NKA01 in trauma resuscitation30% success
• Q4 2026Preclinical data release for septic shock program40% success
• Q3 2026Partnership or grant award for acute lung injury program25% success